Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protalix BioTherapeutics (PLX) Research & Development (2016 - 2025)

Historic Research & Development for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $4.5 million.

  • Protalix BioTherapeutics' Research & Development rose 4899.93% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.1 million, marking a year-over-year increase of 5113.83%. This contributed to the annual value of $13.0 million for FY2024, which is 2412.1% down from last year.
  • Per Protalix BioTherapeutics' latest filing, its Research & Development stood at $4.5 million for Q3 2025, which was up 4899.93% from $6.0 million recorded in Q2 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Research & Development peaked at $8.8 million during Q1 2022, and registered a low of $2.9 million during Q1 2024.
  • For the 5-year period, Protalix BioTherapeutics' Research & Development averaged around $5.4 million, with its median value being $5.6 million (2022).
  • In the last 5 years, Protalix BioTherapeutics' Research & Development crashed by 5062.43% in 2024 and then skyrocketed by 10236.41% in 2025.
  • Over the past 5 years, Protalix BioTherapeutics' Research & Development (Quarter) stood at $7.6 million in 2021, then fell by 26.49% to $5.6 million in 2022, then plummeted by 44.77% to $3.1 million in 2023, then surged by 32.95% to $4.1 million in 2024, then increased by 8.32% to $4.5 million in 2025.
  • Its Research & Development stands at $4.5 million for Q3 2025, versus $6.0 million for Q2 2025 and $3.5 million for Q1 2025.